Wird geladen...
Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players
Glioblastoma (GBM) represents the most frequent glial tumor, with almost 3 new cases per 100,000 people per year. Despite treatment, the prognosis for GBM patients remains extremely poor, with a median survival of 14.6 months, and a 5-year survival less than 5%. It is generally believed that GBM cre...
Gespeichert in:
| Veröffentlicht in: | Oncol Lett |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
D.A. Spandidos
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7583708/ https://ncbi.nlm.nih.gov/pubmed/33123243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.12195 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|